# KLOW Research Record — Component-by-component literature summary > The KLOW research record is monotherapy-only. Mechanism and study summary for each of GHK-Cu, BPC-157, TB-500, and KPV, with citations and the combination-evidence gap documented. The KLOW research record splits cleanly into four monotherapy literatures and one empty cell where the combination study would sit. Both halves are documented here. ## How to read this record The KLOW research record is four separate monotherapy literatures and one conspicuously empty cell where a combination study would sit. The rule for reading it: every finding below belongs to exactly one peptide, studied alone, mostly in cells and rodent models. Do not carry a BPC-157 result over to KPV, and do not sum the four into a KLOW result — no such result exists. BPC-157 has the largest preclinical base: a 2025 systematic review screened 544 papers and found 35 preclinical and one retrospective case series — no randomized human trial. TB-500 has the most human data, from a Phase 1 IV safety study through Phase 2 dermal and Phase 3 ophthalmic work. GHK-Cu's strongest human evidence is topical-cosmetic. KPV has no published human clinical trial. Nothing published has co-administered all four; the combination rationale is mechanistic extrapolation only. ## The combination-evidence gap Before the per-component sections, one disclosure belongs at the top of the sheet. No peer-reviewed in-vivo study has been published of the GHK-Cu + BPC-157 + TB-500 + KPV combination at any ratio. The four components have only been studied as monotherapies in isolated tissues, rodent models, and a small handful of human ophthalmic, dermatologic, and cardiac trials. No published pharmacokinetic profile exists for a KLOW-style four-peptide co-administered formulation — pharmacokinetic interactions, plasma stability of co-blended peptides, and tissue distribution under fixed-ratio dosing are unknown. The combination rationale that vendors and hobbyists offer — that the four peptides cover non-overlapping aspects of tissue repair and inflammation — is mechanistic extrapolation from monotherapy data. It is not direct evidence. ## GHK-Cu — matrix remodeling and transcriptional reach The GHK-Cu literature splits into three threads: dermal wound healing, gene-expression modulation, and adjunct dermatologic applications (hair follicle, ophthalmic surface). Pickart's 2015 review summarized the rodent and human-skin-biopsy wound-healing record: faster wound contraction, increased collagen and elastin synthesis, glycosaminoglycan deposition, and metalloproteinase modulation [6]. Topical formulations used in human work are typically 0.01-0.05%; in cell culture, GHK-Cu acts in the nanomolar-to-micromolar range. A 2012 review documented GHK-Cu activity against oxidative stress and degenerative-aging gene signatures in vitro and in rodent neuronal models [7]. The most striking single finding in the GHK-Cu literature is transcriptional: a Connectivity Map analysis showed GHK reverted a 127-gene COPD-severity signature toward the healthy baseline [8]. The same kind of broad gene-expression reach has been documented in skin-regeneration contexts in Pickart's later reviews. A 2025 narrative review of tripeptides in wound healing covered GHK, KPV, and related peptides as targeting distinct nodes of wound-healing biology — matrix synthesis, anti-inflammation, angiogenesis — and identified combined-formulation evidence as a literature gap [22]. In ex-vivo human hair follicle organ culture and murine dermal papilla cells, copper-tripeptide complexes increased hair shaft elongation and dermal papilla cell proliferation [9]. ## BPC-157 — the largest preclinical base, the thinnest human record The BPC-157 literature is concentrated in musculoskeletal repair, gastric and intestinal mucosal protection, and angiogenesis. In rats, 10 ug/kg intraperitoneal accelerated tendon-to-bone healing in an Achilles detachment model and reversed methylprednisolone-induced healing impairment [1]. Transected Achilles tendon healing was accelerated at 10 ug, 10 ng, and 10 pg per kg, with corresponding in-vitro tendocyte proliferation [4]. A 2021 study in disabled myotendinous junctions showed architectural and functional recovery at 10 ug/kg ip or per-oral [23]. Mechanistically, BPC-157 promotes VEGFR2 internalization and activation in human umbilical vein endothelial cells, with downstream Akt-eNOS signaling; in rat ischemic hindlimb, the same compound increased capillary density and restored perfusion on laser Doppler [2]. In isolated rat aortic rings, BPC-157 produced NO-mediated vasorelaxation through Src-Caveolin-1-eNOS signaling at concentrations from 10 nanomolar to 1 micromolar in the tissue bath [3]. A 2023 review surveyed BPC-157 effects across rodent brain-gut and gut-brain axis models — anxiolytic, anti-cataleptic, and gut-protective effects across multiple lesion paradigms at 10 ug/kg and 10 ng/kg, both intraperitoneal and per-oral in drinking water [17]. The human record is one Phase II trial in ulcerative colitis (PL 14736 enema, conducted by Pliva, Croatia), the results of which were never published [5]. The 2025 HSS Journal systematic review screened 544 articles, included 36, and explicitly noted the absence of independent multi-center replication and the predominance of rat preclinical data [19]. The 2025 Pharmaceuticals literature and patent review catalogued mechanistic pathways and gaps, emphasizing the absence of robust pharmacokinetic profiling in published literature [20]. The 2025 BPC-157 + GHK-Cu wound-healing review synthesized preclinical efficacy across both peptides and reiterated that clinical-grade human data remains limited [21]. ## TB-500 — the most human data of the four Thymosin beta-4 has the deepest human evidence base of any KLOW component. Kleinman and Sosne's 2012 review documented preclinical dermal healing across rat and mouse models and reported approximately one-month acceleration of healing in Phase 2 trials of stasis and pressure ulcers in patients who did heal, with topical formulations at 0.01-0.03% [10]. A separate rat incisional-wound study showed that thymosin beta-4 produced superior collagen organization and reduced scarring versus controls by organizing connective tissue and preventing myofibroblast differentiation [11]. A randomized, placebo-controlled Phase 1 trial of intravenous thymosin beta-4 in healthy human volunteers tested single doses from 42 mg to 1260 mg and a multiple-dose 14-day regimen. No serious adverse events were reported, and the pharmacokinetic profile was favorable [12]. The 2022 ophthalmic Phase 3 trial of 0.1% RGN-259 in neurotrophic keratopathy met its primary endpoint and improved patient-reported comfort versus vehicle [13]. A parallel European Phase 3 SEER-3 trial in neurotrophic keratitis missed its primary endpoint; the authors attributed the miss to an unusually strong placebo response. The most recently advanced TB-500 trial is cardiac. A 2025 study (n=90, 90-day follow-up) reported that IV thymosin beta-4 at 0.5 ug/kg and 1.0 ug/kg, given within 12 hours of PCI and on days 2-7 in STEMI patients, reduced infarct size and improved left-ventricular function versus placebo [18]. This is the most clinically advanced TB-500 work outside ophthalmology. ## KPV — selective delivery to inflamed tissue, no human trial KPV's research base is centered on intestinal inflammation. The Dalmasso 2008 study in Gastroenterology showed that orally delivered KPV — 100 micromolar in drinking water — decreased severity of DSS- and TNBS-induced colitis in mice through PepT1-mediated cellular uptake. Inflammation markers fell by approximately 50%, with proportionate reductions in TNF-alpha, IL-1-beta, and IL-6 [14]. The same group's 2016 follow-up in colitis-associated cancer used the AOM/DSS model and showed reduced tumor count and dysplasia in KPV-treated mice [15]. PepT1 expression is upregulated in inflamed and dysplastic colonic tissue, which explains both the oral activity and the selective accumulation at disease sites. In vitro, alpha-MSH-related peptides including the C-terminal KPV tripeptide reduce NF-kB nuclear translocation and lower TNF-alpha and IL-1-beta secretion in human and murine immune cell cultures [16]. Brzoska's 2003 commentary positioned this class as anti-inflammatory and immunomodulating agents distinct from melanocortin-receptor agonists. The human evidence base for KPV is empty. No published clinical trial. KPV is scheduled for FDA Pharmacy Compounding Advisory Committee review in mid-2026. --- A technical reference set for the peer-reviewed literature — not a clinic, not a vendor, not a prescription.